Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin for heart failure according to body mass index: the DELIVER trial
Carly Adamson, Toru Kondo, Pardeep S. Jhund, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4406-4417
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Mikhail Kosiborod, Steen Z. Abildstrøm, Barry A. Borlaug, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 12, pp. 1069-1084
Open Access | Times Cited: 640
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail Kosiborod, Mark C. Petrie, Barry A. Borlaug, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 15, pp. 1394-1407
Closed Access | Times Cited: 199
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Barry A. Borlaug, Dalane W. Kitzman, Melanie J. Davies, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2358-2365
Open Access | Times Cited: 113
Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial
Barry A. Borlaug, Yogesh N.V. Reddy, A Braun, et al.
Circulation (2023) Vol. 148, Iss. 10, pp. 834-844
Open Access | Times Cited: 53
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Mikhail Kosiborod, Steen Z. Abildstrøm, Barry A. Borlaug, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 8, pp. 1000-1010
Open Access | Times Cited: 52
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail Kosiborod, John Deanfield, Richard Pratley, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 949-961
Closed Access | Times Cited: 49
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 46
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial
Mikhail Kosiborod, Subodh Verma, Barry A. Borlaug, et al.
Circulation (2023) Vol. 149, Iss. 3, pp. 204-216
Open Access | Times Cited: 43
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure
Scott D. Solomon, John W. Ostrominski, Xiaowen Wang, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1587-1602
Open Access | Times Cited: 24
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 20
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 9, pp. 773-785
Open Access | Times Cited: 18
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 16
Obesity: the perfect storm for heart failure
Maria Lembo, Teresa Strisciuglio, Celeste Fonderico, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 1841-1860
Open Access | Times Cited: 12
GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis
Alessandro Villaschi, Giuseppe Ferrante, F. Cannata, et al.
Clinical Research in Cardiology (2024) Vol. 113, Iss. 6, pp. 898-909
Closed Access | Times Cited: 11
Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial
Naveed Sattar, Javed Butler, Matthew M.Y. Lee, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 4, pp. 900-909
Open Access | Times Cited: 9
State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age
Roy Rasalam, Andrew Sindone, Gary Deed, et al.
ESC Heart Failure (2025)
Open Access | Times Cited: 1
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Takeshi Kitai, Shun Kohsaka, Takao Kato, et al.
Journal of Cardiac Failure (2025)
Closed Access | Times Cited: 1
Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction
Mingming Yang, Toru Kondo, Carly Adamson, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1606-1618
Open Access | Times Cited: 19
Obesity, Cardiorenal Comorbidities, and Risk of Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction
Camilla S. Morgen, Christiane L. Haase, Tuğçe Kalaycı Oral, et al.
Mayo Clinic Proceedings (2023) Vol. 98, Iss. 10, pp. 1458-1468
Closed Access | Times Cited: 17
Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
Panagiotis Theofilis, Evangelos Oikonomou, Konstantinos Tsioufis, et al.
Life (2023) Vol. 13, Iss. 2, pp. 497-497
Open Access | Times Cited: 16
Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity
Ayesha Rehman, Shahab Saidullah, Muhammad Asad, et al.
Clinical Cardiology (2024) Vol. 47, Iss. 5
Open Access | Times Cited: 6
Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
John W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan
European Heart Journal (2024) Vol. 45, Iss. 30, pp. 2748-2751
Closed Access | Times Cited: 6
Obesity and Weight Loss Strategies for Patients With Heart Failure
Amanda R. Vest, Philip R. Schauer, Jo E. Rodgers, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 9, pp. 1509-1527
Closed Access | Times Cited: 6
Effects of weight loss in heart failure patients with overweight and obesity: a systematic review and meta-analysis
Meixuan Chi, Yangfan Nie, Yue Su, et al.
European Journal of Preventive Cardiology (2023) Vol. 30, Iss. 17, pp. 1906-1921
Closed Access | Times Cited: 13
Sodium–glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials
Anastasia Adamou, David‐Dimitris Chlorogiannis, Ioannis Kyriakoulis, et al.
Internal and Emergency Medicine (2024) Vol. 19, Iss. 2, pp. 565-573
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top